Drugs / FARGLITAZAR
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT00244751 | Nov 2005 → Mar 2008 | cirrhosis of liver | GlaxoSmithKline | Completed | Missed primary |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | FARGLITAZAR | ChEMBL registry synonym — accepted as the source's own label CHEMBL107367 ↗ |
| Known as | G1-262570 | ChEMBL registry synonym — accepted as the source's own label CHEMBL107367 ↗ |
| Known as | GI-262570X | ChEMBL registry synonym — accepted as the source's own label CHEMBL107367 ↗ |
| Known as | GI262570 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT00244751 ↗ |
| Action | Activate | “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL107367 ↗ |
| Modality | Small molecule | — CHEMBL107367 ↗ |
| Target | PPARG | “Peroxisome proliferator-activated receptor gamma agonist” CHEMBL107367 ↗ |